|
Dear ,
Thank you for subscribing to FierceBiotech. As Editor, I am pleased to welcome you to the Fierce community. FierceBiotech is a concise look at the companies, news and trends shaping the biotechnology industry. We pay specific attention to drug discovery & development, clinical trials, and the FDA approval process. To ensure smooth delivery, please add editors@FierceBiotech.com to your safe senders list and whitelist the domain FierceBiotech.com. We hope you find this coverage to be valuable and an indispensable part of your day. If you ever have any comments, questions, or suggestions to improve the publication, please send me a note. Best,
John D. Carroll
Editor, FierceBiotech
john@fiercebiotech.com
www.FierceBiotech.com P.S. – As a special thank you for subscribing, please feel free to check out our special report on CEO pay: Who makes what in Big Biotech? P.P.S. - We are excited to announce that you can now receive all your biotechnology industry news on your mobile device! To get the mobile edition of FierceBiotech, visit www.FierceBiotech.com/mobile.
| 
